Hanmi Pharmaceutical

Korean pharma maker of long-acting peptide drugs, generics, and an obesity drug in development.

Hanmi's core Korean prescription business is growing and record-profitable, but its obesity-drug upside faces two much bigger rivals already selling in the market, while a governance fight over control sits unresolved.

Hanmi Pharmaceutical makes and sells prescription drugs in South Korea, where it is the number-one choice for doctors writing outpatient prescriptions for eight years running. The company's long-acting peptide platform and existing patent protections are hard for competitors to copy quickly, and its distribution network across Korean pharmacies and hospitals cannot be built overnight, but the real money the company is chasing is a new obesity drug called EPPE that will have to compete directly against Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, which already control 80 percent of that market in Korea. The biggest wild card is a family and management dispute over company control that could force sudden changes in leadership and strategy as soon as late summer 2026, which could reshape how the company executes on the obesity drug launch or any other bets.

• FY2025 revenue hit ₩1.5475 trillion, a company record (2026-02-05)
• Q2 2026 operating profit up 116.9% YoY to ₩131.1 billion (2026-07-28)
• Beijing Hanmi operating profit fell 96.6% YoY on distributor risk (2026-07-29)

• Hanmi Science control dispute between founding family and Chairman Shin could reshuffle board, stake deal closes Aug 7-11 2026. Severity: high
• Beijing Hanmi receivables tied to distributor Runmeikang caused 96.6% Q2 2026 operating profit collapse. Severity: medium
• EPPE launching into obesity market where Novo Nordisk and Eli Lilly hold over 80% combined share. Severity: medium
• Up to $1.185B in Eli Lilly GLP-2 milestone payments are contingent on future trial success, not guaranteed revenue. Severity: low

Is Hanmi Pharmaceutical in financial trouble?

No, the numbers point the other way: FY2025 revenue hit $1.15B (KRW 1.5475T) with operating profit up 19.2% and net profit up 33.9% year over year, reported February 4, 2026. Beijing Hanmi also topped KRW 400B in annual revenue for the first time as of May 8, 2026, and R&D spending stood at 14.8% of revenue (KRW 229.0B) as of March 30, 2026, showing continued investment rather than retrenchment.

Who are Hanmi Pharmaceutical's biggest competitors?

In obesity drugs, Hanmi trails Novo Nordisk's Wegovy, which held about 80% of Korea's obesity-drug market in H1 2025-2026, and also competes with Eli Lilly's Mounjaro. Domestically it races Yuhan and Daewoong, while a wave of more than 60 late-stage Chinese GLP-1 biotechs as of February 2026 adds further pressure in the broader diabetes and weight-loss category.

Is Hanmi Pharmaceutical at risk from AI?

Not directly. AI drug-discovery tools are speeding up rivals' pipelines but have not displaced Hanmi's own LAPSCOVERY peptide platform or its established sales base as of the July 2026 assessment. AI is not currently viewed as a threat vector to Hanmi's business.

What is Hanmi Pharmaceutical's biggest risk?

The main risk flagged is not competitive but internal: an unresolved governance fight between the founding family and CEO Shin Dong-kuk that could unsettle strategy or ownership control. A four-party shareholder agreement is set to expire in 2029, and renewed conflict or renegotiation could surface before December 2028, which is the key watch-item for the company's stability.

How strong is Hanmi's position in obesity drugs?

Hanmi is still an early-stage challenger here. Its triple agonist HM15275 is in Phase 2, with data expected by mid-2027 to show whether it approaches a 25% or greater weight loss target, while Novo Nordisk's Wegovy already commands roughly 80% of Korea's obesity market as of H1 2025-2026. Licensing income, including up to $1.26B from Eli Lilly for sonefpeglutide rights announced May 31, 2026, gives Hanmi funding to keep pursuing the space even though its obesity drug is unproven against market leaders.

What gives Hanmi Pharmaceutical its competitive edge?

Hanmi's edge comes from a strong regulatory track record, established distribution in Korea and China, and eight straight years as Korea's top prescription seller. Large licensing upfronts, such as the Eli Lilly deal worth up to $1.26B (May 31, 2026), add financial cushion that most of the 185 companies in its category do not have.

• 2026-07-30Beijing Hanmi Q2 sales fall 29.9% YoY to 60.7B won on Runmeikang receivables risk
• 2026-07-29Hanmi finalizes EPPE brand name; Phase 3 shows 9.75% weight loss at 40 weeks
• 2026-07-29H1 2026 results: sales 860.2B won (+14.4% YoY), operating profit 184.7B won (+54.6%)
• 2026-07-28Q2 2026 operating profit surges 116.9% YoY to 131.1B won
• 2026-07-08Chairman Shin buys son Lim Jong-yoon's 5.27% stake for 172.7B won, closing Aug 7-11
• 2026-07-02Founding family alliance stake (31.05%) surpasses Chairman Shin's (29.83%)
• 2026-06-02Hanmi licenses GLP-2 drug sonepegglutide to Eli Lilly, deal worth up to $1.26B
• 2026-05-18Hanmi starts Korean Phase 3 diabetes trial for efpeglenatide
• 2026-02-05FY2025 record results: revenue 1.5475T won, operating profit 257.8B won

• Hanmi Pharmaceutical Delivers Record Results as Revenue Reaches USD 1.15 Billion (2026-02-05)
• Hanmi Pharm's Q2 operating profit doubles on Rosuzet growth, Eli Lilly licensing deal (2026-07-29)
• Hanmi Pharmaceutical Q2 Operating Profit Surges 116.9% (2026-07-28)
• Hanmi Pharm
• gurufocus.com (2026-07-30)
• Hanmi Pharmaceutical Licenses GLP-2 Drug Candidate to Eli Lilly in $1.26 Billion Deal (2026-06-02)
• Hanmi Pharmaceutical Unveils First Domestic Obesity Drug 'EPPE' (2026-07-29)
• Hanmi starts phase 3 diabetes trial for GLP-1 drug ahead of obesity launch (2026-05-18)
• Beijing Hanmi Profit Nearly Vanishes Amid Receivables Concerns (2026-07-30)
• Hanmi Heir Lim Jong-hoon Sells 2.5% Holding Company Stake (2026-07-02)
• Hanmi Pharm family sells Hanmi Science shares to pay inheritance tax
• Hanmi Founding Family Surpasses Chairman Shin's Stake (2026-07-02)